Polyrizon Change in Accounts Payable 2023-2024 | PLRZ

Polyrizon change in accounts payable from 2023 to 2024. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

Polyrizon Change in Accounts Payable 2023-2024 | PLRZ

Polyrizon change in accounts payable from 2023 to 2024. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$226.4B
Amgen (AMGN)$166.3B
Gilead Sciences (GILD)$141.3B
Vertex Pharmaceuticals (VRTX)$122.5B
Bristol Myers Squibb (BMY)$99.7B
CSL (CSLLY)$85.2B
GSK (GSK)$77.9B
Regeneron Pharmaceuticals (REGN)$61.8B
Alnylam Pharmaceuticals (ALNY)$42.5B
Argenex SE (ARGX)$35.2B
BioNTech SE (BNTX)$27.5B
Royalty Pharma (RPRX)$20.2B
Insmed (INSM)$19.6B
Biogen (BIIB)$19.2B
Illumina (ILMN)$16.6B
Genmab (GNMSF)$14.9B
Genmab (GMAB)$14.7B
Incyte (INCY)$13.7B
Moderna (MRNA)$13.4B
Exelixis (EXEL)$12.4B
BioMarin Pharmaceutical (BMRN)$11.4B
QIAGEN (QGEN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.4B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.7B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8.1B
Roivant Sciences (ROIV)$7.7B